NEW YORK (GenomeWeb News) – Cardiovascular genomics diagnostics company CardioDx today announced the completion of a $58 million equity financing round.

The company, which recently received Medicare coverage for its coronary artery disease test called Corus CAD, will use the funding to support commercialization of the gene expression test and to develop other genomics diagnostics for cardiovascular disease, it said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.